Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Amarin Set To Go After Expanded TG Market In Q4 2013!

|Includes: Amarin Corporation PLC (AMRN)

With FDA lifting the risk of outcomes study required for Anchor indication approval and locking in a target date early December 2013, I believe this sets the stage for strategic discussions to intensify as Amarin seeks to maximize shareholder value for Anchor indication and beyond. While NCE may still be an overhang, far greater of an overhang once AMRN launched Vascepa on its own was the risk that FDA would make AMRN wait to market Vascepa for the expanded Anchor indication with outcome results required. That is not the case and now any interested suitor would assume they can market against Anchor beginning end of the year. I would not want to be caught short within the next few months. More with a complete article that covers the following to come:

-sNDA approval and what it means for strategic options

-NCE/NME for dummies

-Vascepa scripts and what impact they have on company value

-Update on company staff and approach to investor communication